A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia

Exclusion Criteria

• •Known severe allergic reactions to tocilizumab or other monoclonal antibodies
• •Known hypersensitivity to remdesivir, the metabolites, or formulation excipients
• •Active tuberculosis (TB) infection
• •Suspected active bacterial, fungal, viral, or other infection (besides COVID-19)
• •In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments
• •Treatment with immunosuppressive or immunomodulatory therapy (including tocilizumab) within the past 3 months
• •Concurrent treatment with other agents with actual or possible direct-acting antiviral activity against SARS-CoV-2 within 24 hours prior to study drug dosing. In addition, participants with prior or current treatment with \> 2 doses of remdesivir for COVID-19 are excluded
• •Participating in other drug clinical trials
• •Estimated glomerular filtration rate (eGFR) \< 30 mL/min (including patients receiving hemodialysis or hemofiltration)
• •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 5 x upper limit of normal (ULN) detected within 24 hours of screening (according to local laboratory reference ranges)
• •Absolute neutrophil count (ANC) \< 1000/uL at screening
• •Platelet count \< 50,000/uL at screening
• •Body weight \< 40 kg
• •Treatment with an investigational drug within 5 half-lives or 30 days (whichever is longer) of randomization